Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Vaccines

  Free Subscription


Articles published in Proc Natl Acad Sci U S A

Retrieve available abstracts of 104 articles:
HTML format



Single Articles


    March 2024
  1. CHANG S, Shin KS, Park B, Park S, et al
    Strategy to develop broadly effective multivalent COVID-19 vaccines against emerging variants based on Ad5/35 platform.
    Proc Natl Acad Sci U S A. 2024;121:e2313681121.
    PubMed     Abstract available


    February 2024
  2. RAINS SA, Richards AS
    US state vaccine mandates did not influence COVID-19 vaccination rates but reduced uptake of COVID-19 boosters and flu vaccines compared to bans on vaccine restrictions.
    Proc Natl Acad Sci U S A. 2024;121:e2313610121.
    PubMed     Abstract available


  3. XU D, Powell AE, Utz A, Sanyal M, et al
    Design of universal Ebola virus vaccine candidates via immunofocusing.
    Proc Natl Acad Sci U S A. 2024;121:e2316960121.
    PubMed     Abstract available


    January 2024
  4. MA F, Xu Q, Wang A, Yang D, et al
    A universal design of restructured dimer antigens: Development of a superior vaccine against the paramyxovirus in transgenic rice.
    Proc Natl Acad Sci U S A. 2024;121:e2305745121.
    PubMed     Abstract available


  5. FINNEY J, Moseman AP, Kong S, Watanabe A, et al
    Protective human antibodies against a conserved epitope in pre- and postfusion influenza hemagglutinin.
    Proc Natl Acad Sci U S A. 2024;121:e2316964120.
    PubMed     Abstract available


    December 2023
  6. RAO X, Zhao R, Tong Z, Guo S, et al
    Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of immune-evaded antibodies to neutralize Omicron SARS-CoV-2.
    Proc Natl Acad Sci U S A. 2023;120:e2314193120.
    PubMed     Abstract available


  7. YE Z, Bonam SR, McKay LGA, Plante JA, et al
    Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants.
    Proc Natl Acad Sci U S A. 2023;120:e2311752120.
    PubMed     Abstract available


  8. TORCHE F, Nobles J
    Vaccination, immunity, and the changing impact of COVID-19 on infant health.
    Proc Natl Acad Sci U S A. 2023;120:e2311573120.
    PubMed     Abstract available


  9. CHENG CW, Wu CY, Wang SW, Chen JY, et al
    Low-sugar universal mRNA vaccine against coronavirus variants with deletion of glycosites in the S2 or stem of SARS-CoV-2 spike messenger RNA (mRNA).
    Proc Natl Acad Sci U S A. 2023;120:e2314392120.
    PubMed     Abstract available


    November 2023
  10. ZHOU J, Sukhova K, Peacock TP, McKay PF, et al
    Omicron breakthrough infections in vaccinated or previously infected hamsters.
    Proc Natl Acad Sci U S A. 2023;120:e2308655120.
    PubMed     Abstract available


    October 2023
  11. EDGAR JE, Trezise S, Anthony RM, Krammer F, et al
    Antibodies elicited in humans upon chimeric hemagglutinin-based influenza virus vaccination confer FcgammaR-dependent protection in vivo.
    Proc Natl Acad Sci U S A. 2023;120:e2314905120.
    PubMed     Abstract available


  12. WANG C, Karlsson A, Oguin TH 3rd, Macintyre AN, et al
    Transient inhibition of lysosomal functions potentiates nucleic acid vaccines.
    Proc Natl Acad Sci U S A. 2023;120:e2306465120.
    PubMed     Abstract available


  13. FISCHER H, Huff M, Anders G, Said N, et al
    Metacognition, public health compliance, and vaccination willingness.
    Proc Natl Acad Sci U S A. 2023;120:e2105425120.
    PubMed     Abstract available


  14. CHUNG YH, Ortega-Rivera OA, Volckaert BA, Jung E, et al
    Viral nanoparticle vaccines against S100A9 reduce lung tumor seeding and metastasis.
    Proc Natl Acad Sci U S A. 2023;120:e2221859120.
    PubMed     Abstract available


  15. XU J, Zhang Y, Qu P, Shamseldin MM, et al
    A next-generation intranasal trivalent MMS vaccine induces durable and broad protection against SARS-CoV-2 variants of concern.
    Proc Natl Acad Sci U S A. 2023;120:e2220403120.
    PubMed     Abstract available


    August 2023
  16. RAPPUOLI R
    Emil Gotschlich: Physician-scientist and vaccine pioneer (1935-2023).
    Proc Natl Acad Sci U S A. 2023;120:e2312256120.
    PubMed    


  17. ZHU J, Gao X, Li Y, Zhang Z, et al
    Human FAM111A inhibits vaccinia virus replication by degrading viral protein I3 and is antagonized by poxvirus host range factor SPI-1.
    Proc Natl Acad Sci U S A. 2023;120:e2304242120.
    PubMed     Abstract available


  18. SHEPHERD SJ, Han X, Mukalel AJ, El-Mayta R, et al
    Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines.
    Proc Natl Acad Sci U S A. 2023;120:e2303567120.
    PubMed     Abstract available


  19. YANG L, Wang Z, Wang L, Vrancken B, et al
    Association of vaccination, international travel, public health and social measures with lineage dynamics of SARS-CoV-2.
    Proc Natl Acad Sci U S A. 2023;120:e2305403120.
    PubMed     Abstract available


    July 2023
  20. ZHANG P, Falcone S, Tsybovsky Y, Singh M, et al
    Increased neutralization potency and breadth elicited by a SARS-CoV-2 mRNA vaccine forming virus-like particles.
    Proc Natl Acad Sci U S A. 2023;120:e2305896120.
    PubMed     Abstract available


  21. TOCKARY TA, Abbasi S, Matsui-Masai M, Hayashi A, et al
    Comb-structured mRNA vaccine tethered with short double-stranded RNA adjuvants maximizes cellular immunity for cancer treatment.
    Proc Natl Acad Sci U S A. 2023;120:e2214320120.
    PubMed     Abstract available


  22. PRASAD PV, Steele MK, Reed C, Meyers LA, et al
    Multimodeling approach to evaluating the efficacy of layering pharmaceutical and nonpharmaceutical interventions for influenza pandemics.
    Proc Natl Acad Sci U S A. 2023;120:e2300590120.
    PubMed     Abstract available


    June 2023
  23. BEN-AKIVA E, Karlsson J, Hemmati S, Yu H, et al
    Biodegradable lipophilic polymeric mRNA nanoparticles for ligand-free targeting of splenic dendritic cells for cancer vaccination.
    Proc Natl Acad Sci U S A. 2023;120:e2301606120.
    PubMed     Abstract available


  24. URBONAVICIUTE V, Romero-Castillo L, Xu B, Luo H, et al
    Therapy targeting antigen-specific T cells by a peptide-based tolerizing vaccine against autoimmune arthritis.
    Proc Natl Acad Sci U S A. 2023;120:e2218668120.
    PubMed     Abstract available


    May 2023
  25. AMAYA L, Grigoryan L, Li Z, Lee A, et al
    Circular RNA vaccine induces potent T cell responses.
    Proc Natl Acad Sci U S A. 2023;120:e2302191120.
    PubMed     Abstract available



  26. Correction for Arpino et al., COVID-19 precautionary behaviors and vaccine acceptance among older individuals: The role of close kin.
    Proc Natl Acad Sci U S A. 2023;120:e2305288120.
    PubMed    


    April 2023
  27. LEE CY, Raghunathan V, Caceres CJ, Geiger G, et al
    Epistasis reduces fitness costs of influenza A virus escape from stem-binding antibodies.
    Proc Natl Acad Sci U S A. 2023;120:e2208718120.
    PubMed     Abstract available


  28. SONG Y, Bell DR, Ahmed R, Chan KC, et al
    A mutagenesis study of autoantigen optimization for potential T1D vaccine design.
    Proc Natl Acad Sci U S A. 2023;120:e2214430120.
    PubMed     Abstract available


    March 2023
  29. ARPINO B, Bordone V, Di Gessa G
    COVID-19 precautionary behaviors and vaccine acceptance among older individuals: The role of close kin.
    Proc Natl Acad Sci U S A. 2023;120:e2214382120.
    PubMed     Abstract available


  30. GRIFFITHS ME, Meza DK, Haydon DT, Streicker DG, et al
    Inferring the disruption of rabies circulation in vampire bat populations using a betaherpesvirus-vectored transmissible vaccine.
    Proc Natl Acad Sci U S A. 2023;120:e2216667120.
    PubMed     Abstract available


  31. LIU Z, Zhou J, Wang X, Xu W, et al
    A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates.
    Proc Natl Acad Sci U S A. 2023;120:e2221713120.
    PubMed     Abstract available


    February 2023
  32. WAN J, Ren L, Li X, He S, et al
    Photoactivatable nanoagonists chemically programmed for pharmacokinetic tuning and in situ cancer vaccination.
    Proc Natl Acad Sci U S A. 2023;120:e2210385120.
    PubMed     Abstract available


    January 2023
  33. ATHEY S, Grabarz K, Luca M, Wernerfelt N, et al
    Digital public health interventions at scale: The impact of social media advertising on beliefs and outcomes related to COVID vaccines.
    Proc Natl Acad Sci U S A. 2023;120:e2208110120.
    PubMed     Abstract available


  34. DISTLER ME, Cavaliere JP, Teplensky MH, Evangelopoulos M, et al
    Molecular DNA dendron vaccines.
    Proc Natl Acad Sci U S A. 2023;120:e2215091120.
    PubMed     Abstract available


  35. NAJM R, Ruivo MTG, Penarete-Vargas DM, Hamie M, et al
    Invasion of Toxoplasma gondii bradyzoites: Molecular dissection of the moving junction proteins and effective vaccination targets.
    Proc Natl Acad Sci U S A. 2023;120:e2219533120.
    PubMed     Abstract available


  36. VOUTOURI C, Hardin CC, Naranbhai V, Nikmaneshi MR, et al
    Mechanistic model for booster doses effectiveness in healthy, cancer, and immunosuppressed patients infected with SARS-CoV-2.
    Proc Natl Acad Sci U S A. 2023;120:e2211132120.
    PubMed     Abstract available


  37. LUO S, Jing C, Ye AY, Kratochvil S, et al
    Humanized V(D)J-rearranging and TdT-expressing mouse vaccine models with physiological HIV-1 broadly neutralizing antibody precursors.
    Proc Natl Acad Sci U S A. 2023;120:e2217883120.
    PubMed     Abstract available


    December 2022
  38. PECETTA S, Rappuoli R
    mRNA, the beginning of a new influenza vaccine game.
    Proc Natl Acad Sci U S A. 2022;119:e2217533119.
    PubMed    


    November 2022
  39. MCMAHON M, O'Dell G, Tan J, Sarkozy A, et al
    Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses.
    Proc Natl Acad Sci U S A. 2022;119:e2206333119.
    PubMed     Abstract available


    October 2022
  40. YANG K, Wang C, Kreutzberger AJB, Ojha R, et al
    Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the prehairpin intermediate of the spike protein.
    Proc Natl Acad Sci U S A. 2022;119:e2210990119.
    PubMed     Abstract available


    September 2022
  41. VAN BEEK M, Nussenzweig MC, Chakraborty AK
    Two complementary features of humoral immune memory confer protection against the same or variant antigens.
    Proc Natl Acad Sci U S A. 2022;119:e2205598119.
    PubMed     Abstract available


    August 2022
  42. LU M, Chamblee M, Zhang Y, Ye C, et al
    SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern.
    Proc Natl Acad Sci U S A. 2022;119:e2110105119.
    PubMed     Abstract available


  43. YANG Z, Wu D, Lu S, Qiu Y, et al
    Plasma metabolome and cytokine profile reveal glycylproline modulating antibody fading in convalescent COVID-19 patients.
    Proc Natl Acad Sci U S A. 2022;119:e2117089119.
    PubMed     Abstract available


  44. XIONG H, Sun H, Wang S, Yuan L, et al
    The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2.
    Proc Natl Acad Sci U S A. 2022;119:e2204256119.
    PubMed     Abstract available


  45. CHEN J, Ye Z, Huang C, Qiu M, et al
    Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8(+) T cell response.
    Proc Natl Acad Sci U S A. 2022;119:e2207841119.
    PubMed     Abstract available


  46. ZHANG Y, Lu M, Mahesh KC, Kim E, et al
    A highly efficacious live attenuated mumps virus-based SARS-CoV-2 vaccine candidate expressing a six-proline stabilized prefusion spike.
    Proc Natl Acad Sci U S A. 2022;119:e2201616119.
    PubMed     Abstract available


  47. BACKLUND CM, Holden RL, Moynihan KD, Garafola D, et al
    Cell-penetrating peptides enhance peptide vaccine accumulation and persistence in lymph nodes to drive immunogenicity.
    Proc Natl Acad Sci U S A. 2022;119:e2204078119.
    PubMed     Abstract available


  48. TOWNSEND JP, Hassler HB, Sah P, Galvani AP, et al
    The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2.
    Proc Natl Acad Sci U S A. 2022;119:e2204336119.
    PubMed     Abstract available


    July 2022
  49. RABB N, Bowers J, Glick D, Wilson KH, et al
    The influence of social norms varies with "others" groups: Evidence from COVID-19 vaccination intentions.
    Proc Natl Acad Sci U S A. 2022;119:e2118770119.
    PubMed     Abstract available


  50. KARDAVA L, Rachmaninoff N, Lau WW, Buckner CM, et al
    Early human B cell signatures of the primary antibody response to mRNA vaccination.
    Proc Natl Acad Sci U S A. 2022;119:e2204607119.
    PubMed     Abstract available


    June 2022
  51. SIEWERT LK, Korotaev A, Sedzicki J, Fromm K, et al
    Identification of the Bartonella autotransporter CFA as a protective antigen and hypervariable target of neutralizing antibodies in mice.
    Proc Natl Acad Sci U S A. 2022;119:e2202059119.
    PubMed     Abstract available


  52. AMERICO JL, Cotter CA, Earl PL, Liu R, et al
    Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.
    Proc Natl Acad Sci U S A. 2022;119:e2202069119.
    PubMed     Abstract available


  53. OTIANG E, Yoder J, Manian S, Campbell ZA, et al
    Vaccination of household chickens results in a shift in young children's diet and improves child growth in rural Kenya.
    Proc Natl Acad Sci U S A. 2022;119:e2122389119.
    PubMed     Abstract available


  54. NARCISO AR, Iovino F, Thorsdottir S, Mellroth P, et al
    Membrane particles evoke a serotype-independent cross-protection against pneumococcal infection that is dependent on the conserved lipoproteins MalX and PrsA.
    Proc Natl Acad Sci U S A. 2022;119:e2122386119.
    PubMed     Abstract available


    May 2022
  55. HEKMATI A, Luhar M, Krishnamachari B, Mataric M, et al
    Simulating COVID-19 classroom transmission on a university campus.
    Proc Natl Acad Sci U S A. 2022;119:e2116165119.
    PubMed     Abstract available


  56. BAXTER-KING R, Brown JR, Enos RD, Naeim A, et al
    How local partisan context conditions prosocial behaviors: Mask wearing during COVID-19.
    Proc Natl Acad Sci U S A. 2022;119:e2116311119.
    PubMed     Abstract available


  57. ZHU X, Han J, Sun W, Puente-Massaguer E, et al
    Influenza chimeric hemagglutinin structures in complex with broadly protective antibodies to the stem and trimer interface.
    Proc Natl Acad Sci U S A. 2022;119:e2200821119.
    PubMed     Abstract available


  58. KINGSTAD-BAKKE B, Lee W, Chandrasekar SS, Gasper DJ, et al
    Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants.
    Proc Natl Acad Sci U S A. 2022;119:e2118312119.
    PubMed     Abstract available


  59. SPRECO A, Schon T, Timpka T
    Corruption should be taken into account when considering COVID-19 vaccine allocation.
    Proc Natl Acad Sci U S A. 2022;119:e2122664119.
    PubMed    


  60. DUCH R, Robinson TS, Clarke PM, Roope LSJ, et al
    Reply to Spreco et al.: Perceived corruption and preferences for COVID-19 vaccine allocations.
    Proc Natl Acad Sci U S A. 2022;119:e2201847119.
    PubMed    


    April 2022
  61. POSTIGO-FERNANDEZ J, Firdessa-Fite R, Creusot RJ
    Preclinical evaluation of a precision medicine approach to DNA vaccination in type 1 diabetes.
    Proc Natl Acad Sci U S A. 2022;119:e2110987119.
    PubMed     Abstract available


  62. ROBINSON PC, Liew DFL, Tanner HL, Grainger JR, et al
    COVID-19 therapeutics: Challenges and directions for the future.
    Proc Natl Acad Sci U S A. 2022;119:e2119893119.
    PubMed     Abstract available


  63. TEPLENSKY MH, Distler ME, Kusmierz CD, Evangelopoulos M, et al
    Spherical nucleic acids as an infectious disease vaccine platform.
    Proc Natl Acad Sci U S A. 2022;119:e2119093119.
    PubMed     Abstract available


    March 2022
  64. KAVISHNA R, Kang TY, Vacca M, Chua BYL, et al
    A single-shot vaccine approach for the universal influenza A vaccine candidate M2e.
    Proc Natl Acad Sci U S A. 2022;119:e2025607119.
    PubMed     Abstract available


  65. SCHMELZ K, Bowles S
    Opposition to voluntary and mandated COVID-19 vaccination as a dynamic process: Evidence and policy implications of changing beliefs.
    Proc Natl Acad Sci U S A. 2022;119:e2118721119.
    PubMed     Abstract available


  66. FOSTER SL, Woolsey C, Borisevich V, Agans KN, et al
    A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease.
    Proc Natl Acad Sci U S A. 2022;119:e2200065119.
    PubMed     Abstract available


  67. LEWNARD JA, Fries LF, Cho I, Chen J, et al
    Prevention of antimicrobial prescribing among infants following maternal vaccination against respiratory syncytial virus.
    Proc Natl Acad Sci U S A. 2022;119:e2112410119.
    PubMed     Abstract available


  68. WANG X, Li P, Singh AK, Zhang X, et al
    Remodeling Yersinia pseudotuberculosis to generate a highly immunogenic outer membrane vesicle vaccine against pneumonic plague.
    Proc Natl Acad Sci U S A. 2022;119:e2109667119.
    PubMed     Abstract available


  69. WANG R, Suzuki S, Guest JD, Heller B, et al
    Induction of broadly neutralizing antibodies using a secreted form of the hepatitis C virus E1E2 heterodimer as a vaccine candidate.
    Proc Natl Acad Sci U S A. 2022;119:e2112008119.
    PubMed     Abstract available


  70. SHAN S, Luo S, Yang Z, Hong J, et al
    Deep learning guided optimization of human antibody against SARS-CoV-2 variants with broad neutralization.
    Proc Natl Acad Sci U S A. 2022;119:e2122954119.
    PubMed     Abstract available


  71. WU CY, Cheng CW, Kung CC, Liao KS, et al
    Glycosite-deleted mRNA of SARS-CoV-2 spike protein as a broad-spectrum vaccine.
    Proc Natl Acad Sci U S A. 2022;119.
    PubMed     Abstract available


  72. PETERSEN GEL, Buntjer JB, Hely FS, Byrne TJ, et al
    Modeling suggests gene editing combined with vaccination could eliminate a persistent disease in livestock.
    Proc Natl Acad Sci U S A. 2022;119.
    PubMed     Abstract available


    February 2022
  73. WIECEK W, Ahuja A, Chaudhuri E, Kremer M, et al
    Testing fractional doses of COVID-19 vaccines.
    Proc Natl Acad Sci U S A. 2022;119.
    PubMed     Abstract available


  74. DEVARAJAN P, Vong AM, Castonguay CH, Kugler-Umana O, et al
    Strong influenza-induced TFH generation requires CD4 effectors to recognize antigen locally and receive signals from continuing infection.
    Proc Natl Acad Sci U S A. 2022;119.
    PubMed     Abstract available


  75. HOFF NA, Bratcher A, Kelly JD, Musene K, et al
    Immunogenicity of rVSVDeltaG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo.
    Proc Natl Acad Sci U S A. 2022;119.
    PubMed     Abstract available


  76. MILKMAN KL, Gandhi L, Patel MS, Graci HN, et al
    A 680,000-person megastudy of nudges to encourage vaccination in pharmacies.
    Proc Natl Acad Sci U S A. 2022;119.
    PubMed     Abstract available


  77. MILDER FJ, Jongeneelen M, Ritschel T, Bouchier P, et al
    Universal stabilization of the influenza hemagglutinin by structure-based redesign of the pH switch regions.
    Proc Natl Acad Sci U S A. 2022;119.
    PubMed     Abstract available


  78. BEANS C
    Researchers getting closer to a "universal" flu vaccine.
    Proc Natl Acad Sci U S A. 2022;119.
    PubMed    


    January 2022
  79. VARRELMAN TJ, Remien CH, Basinski AJ, Gorman S, et al
    Quantifying the effectiveness of betaherpesvirus-vectored transmissible vaccines.
    Proc Natl Acad Sci U S A. 2022;119.
    PubMed     Abstract available


  80. GANDON S, Lion S
    Targeted vaccination and the speed of SARS-CoV-2 adaptation.
    Proc Natl Acad Sci U S A. 2022;119.
    PubMed     Abstract available


  81. HUPERT N, Marin-Hernandez D, Gao B, Aguas R, et al
    Heterologous vaccination interventions to reduce pandemic morbidity and mortality: Modeling the US winter 2020 COVID-19 wave.
    Proc Natl Acad Sci U S A. 2022;119.
    PubMed     Abstract available


    December 2021
  82. SHAFFER L
    Inner Workings: Using vaccines to harness the immune system and fight drugs of abuse.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed    


  83. JAMIESON KH, Romer D, Jamieson PE, Winneg KM, et al
    The role of non-COVID-specific and COVID-specific factors in predicting a shift in willingness to vaccinate: A panel study.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


  84. SALOMON JA, Reinhart A, Bilinski A, Chua EJ, et al
    The US COVID-19 Trends and Impact Survey: Continuous real-time measurement of COVID-19 symptoms, risks, protective behaviors, testing, and vaccination.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


  85. NAIR P
    QnAs with Katalin Kariko.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed    


  86. LIU X, Luongo C, Matsuoka Y, Park HS, et al
    A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


  87. CHU J, Pink SL, Willer R
    Religious identity cues increase vaccination intentions and trust in medical experts among American Christians.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


  88. BOKEMPER SE, Gerber AS, Omer SB, Huber GA, et al
    Persuading US White evangelicals to vaccinate for COVID-19: Testing message effectiveness in fall 2020 and spring 2021.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    November 2021
  89. NARR K, Ertuna YI, Fallet B, Cornille K, et al
    Vaccine-elicited CD4 T cells prevent the deletion of antiviral B cells in chronic infection.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


  90. ADAM D
    News Feature: Biology research, no cells required: By borrowing the machinery of life from broken cells, researchers are producing novel proteins, cheap lab reagents, and just-add-water vaccines.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed    


  91. PEDERSON T
    A layperson encounter, on the "modified" RNA world.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


  92. XIA D, Jin R, Byagathvalli G, Yu H, et al
    An ultra-low-cost electroporator with microneedle electrodes (ePatch) for SARS-CoV-2 vaccination.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


  93. PISHESHA N, Harmand TJ, Rothlauf PW, Praest P, et al
    A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    October 2021
  94. GUTIERREZ-ALVAREZ J, Honrubia JM, Sanz-Bravo A, Gonzalez-Miranda E, et al
    Middle East respiratory syndrome coronavirus vaccine based on a propagation-defective RNA replicon elicited sterilizing immunity in mice.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


  95. HUGHES MT, Auwaerter PG, Ehmann MR, Garibaldi BT, et al
    Opinion: The importance of offering vaccine choice in the fight against COVID-19.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed    


  96. HENSEN L, Nguyen THO, Rowntree LC, Damelang T, et al
    Robust and prototypical immune responses toward influenza vaccines in the high-risk group of Indigenous Australians.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


  97. GARCIA-SASTRE A
    Genomics serology to inform therapies and vaccines for arthritogenic alphaviruses.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed    


    September 2021
  98. XU S, McGinnis KR, Liu Y, Huang P, et al
    Structural basis of P[II] rotavirus evolution and host ranges under selection of histo-blood group antigens.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    August 2021
  99. KAUGARS K, Dardick J, de Oliveira AP, Weiss KA, et al
    A recombinant herpes virus expressing influenza hemagglutinin confers protection and induces antibody-dependent cellular cytotoxicity.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    May 2021
  100. MCDERMOTT A
    Core Concept: Herd immunity is an important-and often misunderstood-public health phenomenon.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed    


  101. LABUDA JC, Pham OH, Depew CE, Fong KD, et al
    Circulating immunity protects the female reproductive tract from Chlamydia infection.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    April 2021
  102. LIN X, Twelkmeyer T, Zhu D, Zhang L, et al
    Homeostatic regulation of T follicular helper and antibody response to particle antigens by IL-1Ra of medullary sinus macrophage origin.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    March 2021
  103. LE NOUEN C, McCarty T, Yang L, Brown M, et al
    Rescue of codon-pair deoptimized respiratory syncytial virus by the emergence of genomes with very large internal deletions that complemented replication.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


  104. LU EY, Chen HH, Zhao H, Ozawa S, et al
    Health and economic impact of the pneumococcal conjugate vaccine in hindering antimicrobial resistance in China.
    Proc Natl Acad Sci U S A. 2021;118:e2004933118.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.